Trial Profile

A phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of CTM012 in patients with advanced solid tumors.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EXP 011 (Primary)
Indications Neuroendocrine carcinoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

06 Apr 2026 New trial record
18 Mar 2026 According to Excalipoint Therapeutics media release, first patient has been dosed in October 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com